| Literature DB >> 22469519 |
Marie-France Humblet1, Sébastien Vandeputte, Adelin Albert, Christiane Gosset, Nathalie Kirschvink, Eric Haubruge, Fabienne Fecher-Bourgeois, Paul-Pierre Pastoret, Claude Saegerman.
Abstract
To prioritize 100 animal diseases and zoonoses in Europe, we used a multicriteria decision-making procedure based on opinions of experts and evidence-based data. Forty international experts performed intracategory and intercategory weighting of 57 prioritization criteria. Two methods (deterministic with mean of each weight and probabilistic with distribution functions of weights by using Monte Carlo simulation) were used to calculate a score for each disease. Consecutive ranking was established. Few differences were observed between each method. Compared with previous prioritization methods, our procedure is evidence based, includes a range of fields and criteria while considering uncertainty, and will be useful for analyzing diseases that affect public health.Entities:
Mesh:
Year: 2012 PMID: 22469519 PMCID: PMC3309682 DOI: 10.3201/eid1804.111151
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Fifty-seven criteria used for prioritization method for diseases of food-producing animals and zoonoses and corresponding weight attribution by experts, Europe
| Category, criteria | Minimum | Average | Maximum | Fitting distribution* |
|---|---|---|---|---|
| Epidemiology | ||||
| Illness rate, % | 2.05 | 7.59 | 18.00 | Pert (2,05; 5; 18) |
| Case-fatality rate, % | 4.19 | 9.13 | 18.00 | Pert (4,19; 5; 18) |
| Specificity of pathogen | 0.00 | 4.55 | 10.23 | Uniform (0; 10,23) |
| Mode of transmission | 0.00 | 8.08 | 23.52 | Pert (0; 10; 23,52) |
| Incubation period | 0.00 | 3.43 | 6.00 | Pert (0; 2; 6) |
| Clinical course | 0.00 | 2.93 | 6.00 | Pert (0; 2; 6) |
| Persistence in environment | 0.00 | 6.37 | 12.56 | Pert (0; 5; 12,56) |
| Epizootic potential | 0.00 | 9.92 | 22.50 | Pert (0; 10; 22,5) |
| Evolutive characteristics of pathogen | 1.89 | 6.39 | 18.00 | Pert (0; 5; 18) |
| Clinical disease in cattle | 0.00 | 4.52 | 10.71 | Triang (0; 0; 10,71) |
| Clinical disease in small ruminants | 0.00 | 2.37 | 4.74 | Triang (0; 0; 4,74) |
| Clinical disease in swine | 0.00 | 3.60 | 9.00 | Triang (0; 0; 9) |
| Clinical disease in equines | 0.00 | 2.99 | 10.00 | Pert (0; 2; 10) |
| Clinical disease in poultry | 0.00 | 3.42 | 9.00 | Triang (0; 0; 9) |
| Clinical disease in lagomorphs | 0.00 | 3.42 | 9.00 | Triang (0; 0; 9) |
| Clinical disease in wildlife | 0.00 | 4.39 | 11.25 | Pert (0; 2; 11;25) |
| Presence/absence of vector(s)/reservoir(s) in European Union | 3.07 | 6.90 | 11.25 | Pert (3,07; 5; 11,25) |
| Intercategory weight | 10.00 | 19.67 | 25.00 | Pert (10; 20; 25) |
| Prevention/control | ||||
| Control of reservoir(s) or vector(s) | 0.00 | 6.13 | 10.00 | Uniform (0; 10) |
| Vaccination | 5.00 | 8.63 | 15.00 | Uniform (5; 15) |
| Treatment | 3.00 | 6.63 | 10.00 | Uniform (3; 10) |
| Availability and quality of diagnostic tools | 5.00 | 7.69 | 10.00 | Uniform (5; 10) |
| Knowledge of pathogenic agent | 0.00 | 7.38 | 15.00 | Pert (0; 5; 15) |
| Effectiveness of control measures other than treatment, vaccination, and control of vectors | 1.00 | 7.26 | 10.00 | Uniform (1; 10) |
| Effectiveness of prevention measures other than vaccination | 5.00 | 8.72 | 12.00 | Pert (5; 10; 12) |
| Surveillance of pathogenic agent in European Union or worldwide | 4.00 | 7.57 | 15.00 | Triang (4; 4; 15) |
| Intercategory weight | 10.00 | 18.83 | 25.00 | Pert (10; 20; 25) |
| Economy/trade | ||||
| Losses of productivity (milk, eggs, growth) | 0.00 | 6.35 | 17.14 | Pert (0; 9; 17,14) |
| Additional costs: mandatory slaughtering | 0.00 | 5.11 | 12.95 | Uniform (0; 12,95) |
| Additional costs: treatment, disinfection, labor | 0.00 | 4.40 | 8.57 | Pert (0; 5; 8,57) |
| Limited importation–exportation | 0.00 | 4.40 | 8.57 | Pert (0; 5; 8,57) |
| Disturbance of supply and demand (decrease in prices) | 0.00 | 5.54 | 9.23 | Uniform (0; 9,23) |
| Impact on adjacent sectors (tourism) | 0.00 | 4.80 | 17.14 | Triang (0; 0; 17,14) |
| Impact on cattle industry | 0.00 | 3.29 | 17.14 | Triang (0; 0; 17,14) |
| Impact on small ruminants industry | 0.00 | 3.09 | 8.57 | Uniform (0; 8,57) |
| Impact on swine industry | 0.00 | 1.87 | 8.57 | Triang (0; 0; 8,57) |
| Impact on equine industry | 0.00 | 2.81 | 8.57 | Triang (0; 0; 8,57) |
| Impact on poultry industry | 0.00 | 1.77 | 8.57 | Triang (0; 0; 8,57) |
| Impact on rabbit industry | 0.00 | 2.81 | 8.57 | Triang (0; 0; 8,57) |
| Impact on wildlife industry | 0.00 | 2.81 | 8.57 | Triang (0; 0; 8,57) |
| Zoonotic impact (cost of illness) | 0.00 | 2.17 | 8.96 | Triang (0; 0; 8,57) |
| Zoonotic impact (costs of prevention per person) | 0.00 | 4.59 | 10.75 | Triang (0; 0; 10,75) |
| Intercategory weight | 10.00 | 23.00 | 30.00 | Uniform (10; 30) |
| Public health | ||||
| Zoonotic/common agent | 0.00 | 7.81 | 20.00 | Pert (0; 10; 20) |
| Classification of zoonoses | 0.00 | 5.51 | 11.25 | Pert (0; 6; 11,25) |
| Disease knowledge in humans | 2.40 | 7.27 | 11.25 | Pert (2,4; 5; 11,25) |
| Illness rate, % | 1.01 | 8.08 | 12.00 | Uniform (1,01; 12) |
| Case-fatality rate, % | 1.01 | 9.46 | 18.00 | Pert (1,01; 10; 18) |
| Mode of transmission | 0.00 | 5.71 | 10.59 | Pert (0; 5; 10,59) |
| After effects or negative impact on the patient quality of life | 5.29 | 8.88 | 12.00 | Uniform (5,29; 12) |
| Presence of a control plan | 3.03 | 5.37 | 6.99 | Pert (3,03; 5; 6,99) |
| Epidemic potential | 5.29 | 8.98 | 12.13 | Uniform (5,29; 12,13) |
| Vaccination | 5.00 | 7.49 | 11.25 | Uniform (5; 11,25) |
| Treatment | 5.00 | 7.35 | 11.25 | Uniform (5; 11,25) |
| Availability and quality of diagnostic tools | 5.00 | 8.10 | 15.17 | Triang (5; 5; 15,17) |
| Intercategory weight | 20.00 | 24.67 | 30.00 | Uniform (20; 30) |
| Society | ||||
| Lower human consumption of animals | 0.00 | 7.19 | 15.00 | Uniform (0; 15) |
| Perception of problem by consumer | 0.00 | 6.92 | 12.00 | Uniform (0; 12) |
| Potential impact on media | 0.00 | 6.50 | 20.00 | Uniform (0; 20) |
| Impact on animal welfare and biodiversity | 1.00 | 9.38 | 20.00 | Uniform (0; 20) |
| Intercategory weight | 8.00 | 13.83 | 20.00 | Uniform (8; 20) |
*Pert, program evaluation and review technique; uniform, uniform probability distribution; triang, triangular distribution (www.palisade.com/downloads/manuals/EN/RISK5_EN.pdf).
Fifty-seven criteria used for ranking diseases of food-producing animals and zoonoses classified by category, Europe*
| Epidemiology | Score | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranking | Criteria | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||||||||||||
| 1 | Illness rate, % | <1 | 1–10 | 11–30 | 31–50 | 51–70 | 71–90 | >90 | |||||||||||||||
| 2 | Case-fatality rate, % | <1 | 1–10 | 11–30 | 31–50 | 51–70 | 71–90 | >90 | |||||||||||||||
| 3 | Agent specificity | 1 host species | 2 host species | 3 host species | 4 host species | >4 host species | |||||||||||||||||
| 4 | Mode of transmission | No vector-borne transmission (not contagious) | Contamination by direct contact | Contamination by indirect contact | Vector-borne transmission | Airborne contamination | |||||||||||||||||
| 5 | Incubation period | Not applicable: clinical disease never reported in species considered in the study | <1 d | 1–7 d | 8–14 d | 15–30 d | 1–6 mo | >6–12 mo | >12 mo | ||||||||||||||
| 6 | Clinical course | Not applicable: clinical disease never reported in species considered in the study | <1 d | 1–7 d | 8–14 d | 15–30 d | 1–6 mo | >6–12 mo | >12 mo | ||||||||||||||
| 7 | Environmental persistence | None: no persistence in the environment, no vector(s) or wildlife reservoir(s) identified | Rare: anecdotal isolation in a potential vector(s) or the environment | No data available on presence/survival of pathogenic agent in reservoir(s), vector(s) or the environment | Wildlife reservoir(s)/vector(s): pathogen agent persistent in wildlife reservoir(s) and/or vector(s) | Environment: agent naturally surviving in the environment (soil, water) | |||||||||||||||||
| 8 | Epizootic potential | Never: only sporadic cases, epizootics never reported | Rare: most cases are sporadic; possibility of localized epizootic if conditions are ideal: e.g., abnormal multiplication of reservoir(s) and/or vector(s) | Localized: pathogen characterized by localized epizootic potential essentially related to the transmission mode: e.g., food-borne diseases | (Inter)national: epizootic characteristics well known after introduction, possibility of wide spatiotemporal expansion | ||||||||||||||||||
| 9 | Evolutive characteristics of pathogen | Null: stability of pathogen, stable pathogen–vector(s)/pathogen–reservoir(s) relationships (no impact on pathogenicity) | Rare: some mutations/reassortments observed but without any impact on pathogenicity, stable pathogen–vector(s)/pathogen–reservoir(s) relationships | Moderate/not determined: pathogen not characterized for evolutive characteristics yet (recently discovered, limited means of study), mutations with limited consequences on its virulence; stable pathogen–vector(s)/pathogen–-reservoir(s) relationships | Frequent: genetic variability during replication cycles more or less defined; variability of pathogenicity, species affected, reservoir(s), and vector(s) | High: pathogen has a high mutation rate/frequent genetic reassortments and creation of new pathogenic variants at each cycle: variable pathogenicity, host(s), reservoir(s), and vector(s) | |||||||||||||||||
| 10 | Cattle | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 11 | Small ruminants | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 12 | Swine | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 13 | Equine | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 14 | Poultry | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 15 | Lagomorphs | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 16 | Wildlife | Pathogen never reported as etiologic agent of clinical disease in that species | Accidental: few clinical cases reported, only if conditions are favorable (wound, traumatism, favorable environmental conditions) | Rare: clinical disease reported in few cases and no need for favorable conditions | Occasional: clinical disease occasionally reported and no need for favorable conditions | Frequent: clinical disease frequently reported in that species, but not specifically (multispecies pathogen) | Specific: clinical disease only reported in that species | Reservoir species | |||||||||||||||
| 17 | Presence/absence of vector(s) and/or reservoir(s) in EU | Not vector-borne disease and/or no known reservoir | Absence of vector(s)/reservoir(s) in EU | Localized presence: reservoir(s) and/or vector(s) in a limited area of | Mediterranean region/northern Europe/central Europe: vector(s) and/or reservoir(s) in 1 of these 3 regions, each one covering several member states, presence linked to bioclimatic preferences | Mediterranean region, northern Europe/northern Europe, central Europe: vector(s) and/or reservoir(s) in 1 of both regions according to bioclimatic preferences | Generalized repartition: repartition of vector(s) and/or reservoir(s) in the entire EU (few bioclimatic specificities) | ||||||||||||||||
| Prevention–control | Score | ||||||||||||||||||||||
| Ranking | Criteria | 0 | 1 | 2 | 3 | 4 | |||||||||||||||||
| 1 | Control of reservoir(s) and/or vector(s) | Not applicable: no vector-borne transmission and/or no reservoir(s) known to date | Effective: limited reservoir(s), easy to identify; effective control measures and trapping; reservoir(s)/vector(s) with limited demographic and geographic repartition; extensive scientific knowledge of vector(s)/reservoir(s); possibility of integrated control method | Limited: limited reservoir(s), easy to identify; effective control measures and trapping but not applicable at a large scale; reservoir(s)/vector(s) with a limited demographic and geographic repartition; extensive scientific knowledge of vector(s)/reservoir(s); no integrated control method | Possible but poorly/not effective: reservoirs easy to identify but numerous; control measures and trapping poorly effective (poorly active molecule(s); resistances and/or negative impact on environment); reservoir(s)/vector(s) with a limited demographic and geographic repartition; no scientific knowledge of vector(s)/reservoir(s); no integrated control method | Absent/impossible: vector(s)/reservoir(s) not identified; no effective control measure against vector(s) (no active molecule, ineffective trapping); strong demography and/or wide repartition of vector(s) and/or reservoir(s); no scientific knowledge of vector(s)/reservoir(s); no integrated control method | |||||||||||||||||
| 2 | Vaccination | Not applicable: clinical disease never reported in species considered in the study | Commercialized: commercial vaccine available on a global scale | Local/monospecies: vaccine available at a regional/national scale and/or for a targeted species (not systematically available for a global control plan) | Experimental: experimental vaccine, not commercialized; severe adverse reaction when applied; limited protector effect | Absence: no vaccine available for use in species considered in the study, no experimental vaccine | |||||||||||||||||
| 3 | Treatment | Not applicable: clinical disease never reported in species considered in the study | Available/effective: effective treatment available; recommended in cases of infection; economical and rational from a zootechnical point of view | Available but not recommended: masks clinical course of disease; contrary to the control plan; not justified economically or from a zootechnical point of view | Available but poorly/not effective: treatment with a limited effectiveness; severe adverse reactions; experimental or empirical treatment | Absence: no effective treatment available, no experimental treatment available | |||||||||||||||||
| 4 | Availability and quality of diagnostic tools | High: field test(s) available and easy to use, and highly discriminating sensitivity and specificity | Moderate: tests only used in local/regional laboratories | Low: tests only used in specialized laboratories/national reference laboratory | Absence: no diagnostic tools available | ||||||||||||||||||
| 5 | Knowledge of pathogen | Very high: extensive scientific knowledge of pathogen, extensive scientific literature available on its biology: transmission mode, knowledge of vector(s), infectivity | High: detailed scientific knowledge of pathogen but conflicting scientific results; some elements of pathogen biology are still not elucidated | Moderate: limited scientific knowledge of pathogen because it is still being characterized; pathogen recently discovered/isolated but belonging to a well known and studied family of pathogens; pathogen characterized by multiple variants not characterized | Low: no scientific knowledge of pathogen (multiplication, infectivity, incubation period, transmission mode); pathogen recently discovered or emerging | ||||||||||||||||||
| 6 | Effectiveness of control measures other than treatment, vaccination, and vector(s)/ reservoir(s) control | High: effectiveness of implemented control measures (quarantine, slaughter, and restriction area); effective epidemiologic investigation (origin of the infection rapidly identified and quick implementation of control measures) | Moderate: effectiveness of implemented control measures (quarantine, slaughter, and restriction area); epidemiologic investigation poorly conclusive (incomplete traceability of animals and by-products) | Low: limitation of control measures implemented (quarantine, slaughter, and restriction area), limiting dissemination of pathogen; epidemiologic investigation inconclusive | Null: ineffectiveness of implemented control measures (quarantine, slaughter, and restriction area) and/or control measures not indicated because of characteristics of pathogen; epidemiologic investigation inconclusive | ||||||||||||||||||
| 7 | Effectiveness of prevention other than vaccination and control of vector(s)/ reservoir(s) | High: sanitary certificate; effective traceability of animals and by-products; effective disinfection measures; no contact between domestic and wild animals; effective biosecurity measures | Moderate: no sanitary certificate; effective traceability of animals and by-products; effective disinfection measures; limited or incomplete possibilities to restrict contacts between domestic and wild animals; effective biosecurity measures | Low: no sanitary certificate; incomplete traceability of animals and by-products; ineffective disinfection measures; incomplete restriction of contacts between domestic and wild animals; ineffective biosecurity measures | Null: no sanitary certificate; no traceability of animals and by-products; ineffective disinfection measures; no restriction of contact between domestic and wild animals; ineffective biosecurity measures | ||||||||||||||||||
| 8 | Surveillance of pathogen | Generalized: surveillance implemented by all EU member states (even worldwide surveillance) | Member states at risk: surveillance of pathogen in | Outside EU: pathogen surveyed in non-EU regions | Absent: no surveillance of pathogen | ||||||||||||||||||
| Economy/trade | Score | ||||||||||||||||||||||
| Ranking | Criteria | 0 | 1 | 2 | 3 | ||||||||||||||||||
| Individual data (herd/farmer) | |||||||||||||||||||||||
| 1 | Losses of productivity (milk, eggs, growth) | Null: no impact on animal productivity | Low: losses of productivity <20% | Moderate: losses of productivity of 20%–50% | Severe: losses of productivity >50% | ||||||||||||||||||
| 2 | Additional costs: mandatory slaughtering | Not required | Outbreaks only | Outbreaks and restriction areas | |||||||||||||||||||
| Additional costs: treatment, disinfection | Low: treatment not required (e.g., slaughtering justified from an economic point of view) or absent (virus), application of basic sanitary measures (disinfection, footbath) | Moderate: spontaneous resolution of cases, only the animals with serious clinical signs require treatment, application of basic sanitary measures (disinfection, footbath) | High: systematic treatment of animals with clinical signs; application of stricter sanitary measures | ||||||||||||||||||||
| 3 | Additional costs: vaccination | Low: no vaccination advocated or no vaccination available | Moderate: vaccination not mandatory but possible in particular cases, e.g., avian sector | High: mandatory vaccination | |||||||||||||||||||
| Global (sector/market) | |||||||||||||||||||||||
| 4 | Limitation of importation–exportation | Absent: no impact on the importation/exportation of animal and/or by-products | Local: restrictions of animal and/or by-products movements limited to surveillance areas implemented when an outbreak is confirmed | Regional: animal and/or by-products movements limited in an area greater than the surveillance zone but only in 1 member state | International: perturbation/limitation of importations/exportations of animal and by-products between several member states and/or between member states and countries outside the EU | ||||||||||||||||||
| 5 | Disturbance of supply and demand (decrease in prices) | Absent: no impact on supply and demand | Low: temporary disturbance of supply and demand in a limited area and low impact on prices | Moderate: temporary disturbance of supply and demand and decrease in prices <30% in | High: major disturbance of supply and demand and decrease in prices >30% affecting several member states | ||||||||||||||||||
| 6 | Impact on related sectors (tourism, animal feeds) | Absent: no impact on related sectors | Low: turnover reduction <20% in | Moderate: turnover reduction 20%–50% in | High: turnover reduction >50% in | ||||||||||||||||||
| 7 | Impact on cattle industry | Absent: no impact on cattle industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| 7 | Impact on small ruminants industry | Absent: no impact on small ruminants industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| 7 | Impact on swine industry | Absent: no impact on swine industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| 7 | Impact on equine industry | Absent: no impact on equine industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| 7 | Impact on poultry industry | Absent: no impact on poultry industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| Impact on lagomorph industry | Absent: no impact on poultry industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | |||||||||||||||||||
| 7 | Impact on wildlife industry | Absent: no impact on wildlife industry | Low: increased spends and/or decreased benefits <20% compared with situation before beginning of epizootics | Moderate: increased spends and/or decreased benefits between 20% and 50% compared with situation before beginning of epizootics | High: increased spends and/or decreased benefits >50% compared with situation before beginning of epizootics | ||||||||||||||||||
| Cost of disease in humans | |||||||||||||||||||||||
| 8 | Zoonotic impact (cost of illness) | Absent: nonzoonotic or common† disease | Low: medical consultation facultative, hospitalization not required, treatment for most severe clinical cases with conventional drugs, maximum incapacity 7 d | Moderate: medical consultation necessary, hospitalization of most severe clinical cases, systematic and adapted treatment with conventional drugs, incapacity 8–4 d | High: medical consultation necessary, systematic hospitalization but of variable duration, required and adapted treatment with second line drugs, incapacity >14 d, quarantine may be required | ||||||||||||||||||
| 9 | Zoonotic impact (costs of prevention per person) | Absent: nonzoonotic or common disease | Low: vaccination not advocated, simple and low-cost preventive measures (handwashing, mask carrying, insect repellents) | Moderate: vaccination of populations at risk (YOPI), simple and low-cost preventive measures (handwashing, mask carrying, insect repellents) | High: generalized vaccination recommended, restricting and expensive preventive measures (thermograph, quarantine, home containment) | ||||||||||||||||||
| Public health | Score | ||||||||||||||||||||||
| Ranking | Criteria | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||||||||||||
| 1 | Zoonotic/ common agent† | Not zoonotic or common | Accidental: human clinical disease only when favorable conditions are set (YOPI, high infection pressure, practices at risk, unusual transmission route) | Rare: human clinical disease reported in a minority of cases, without necessity of favorable conditions | Frequent: clinical disease often reported in man (multi-species pathogen) without need for favorable conditions | Systematic: clinical disease systematically reported in humans | |||||||||||||||||
| 2 | Classification of zoonoses | Not zoonotic or common | 1: transmission from wild animals to humans | 1+: transmission from wild animals to humans with further human-to-human transmission(s) | 2: transmission from wild animals to domestic animals to humans | 2+: transmission from wild animals to domestic animals to humans, and further human-to-human transmission(s) | |||||||||||||||||
| 3 | Disease knowledge in humans | Not zoonotic or common | Very high: deep scientific knowledge of pathogen, extensive scientific literature available on its biology: transmission mode, knowledge on vector(s), infectivity | High: detailed scientific knowledge of pathogen but conflicting scientific results; some elements of pathogen biology are still not elucidated | Moderate: limited scientific knowledge of pathogen because it is still being characterized; pathogen recently discovered/isolated but belonging to a well-known and studied family of pathogens; pathogen has multiple variants not characterized | Low: no scientific knowledge of pathogen (multiplication, infectivity, incubation period, transmission mode); pathogen agent recently discovered or emerging | |||||||||||||||||
| 4 | Illness rate, % | Not zoonotic or common | <1 | 1–10 | 11–30 | 31–50 | 51–70 | 71–90 | >90 | ||||||||||||||
| 5 | Case-fatality rate, % | Not zoonotic or common | <1 | 1–10 | 11–30 | 31–50 | 51–70 | 71–90 | >90 | ||||||||||||||
| 6 | Mode of contamination | Not zoonotic or common | No vector-borne transmission (not contagious) | Contamination by direct contact | Contamination by indirect contact | Vector-borne transmission | Airborne contamination | ||||||||||||||||
| 7 | Aftereffects or negative impact on the patients' quality of life | Not zoonotic or common | Null: no after effects | Moderate: % disability <30% but no loss of autonomy | Severe: after effects not enabling a professional activity but no loss of autonomy | Very severe: unable to perform professional activities, loss of autonomy, and personal assistance necessary | |||||||||||||||||
| 8 | Control plan (vaccination, determination of populations at risk, surveillance of the disease, definition of areas at risk) | Not zoonotic or common | Worldwide (EU and other countries): international and coordinated control plan (member states and third-world countries) | Generalized (EU): coordinated control plan implemented in all member states | Targeted: coordinated control plan implemented in | Extracommunautary: absence of a control plan in EU but implemented in third-world countries | Absent: no control plan elaborated and implemented | ||||||||||||||||
| 9 | Epidemic potential | Not zoonotic or common | Never: only sporadic cases, epidemics never reported | Rare: most cases are sporadic but when favorable conditions are set, possibility of localized epidemics, e.g., abnormal multiplication of reservoir(s) and/or vector(s) | Localized: pathogen characterized by localized epidemic; potential pathogenicity essentially related to transmission mode (e.g., food-borne diseases) | (Inter)national: epidemic characteristics well known after introduction, possible a wide spatiotemporal expansion | |||||||||||||||||
| 10 | Vaccination | Not zoonotic or common | Commercialized: commercial vaccine available on a global scale | Local/monospecies: vaccine available at a regional/national scale (not systematically available for a global control plan) | Experimental: experimental vaccine, not commercially available; severe adverse reaction when applied; limited protector effect | Absence: no commercially available or experimental vaccine | |||||||||||||||||
| 11 | Treatment | Not zoonotic or common | Existing/effective: effective treatment commercially available | Available but not recommended: major side effects | Available but poorly effective: treatment with limited effectiveness, partial resistance of pathogen or experimental treatment | Absent: no commercially available or experimental treatment | |||||||||||||||||
| 12 | Availability and quality of diagnostic tools | Not zoonotic or common | High: field test(s) available and easy to use with highly discriminating sensitivity and specificity | Moderate: tests only used in local/regional laboratory | Low: tests only used in specialized laboratories/national reference laboratory | Absence: no diagnostic tools available | |||||||||||||||||
| Society | Score | ||||||||||||||||||||||
| Ranking | Criteria | 0 | 1 | 2 | 3 | 4 | |||||||||||||||||
| 1 | Lower human consumption of animals | No: no impact on consumption | Low: impact on consumption and a decrease <20% compared with previous consumption | Moderate: impact on consumption and a decrease of 20%–50% compared with previous consumption | High: impact on consumption and a decrease >50% compared with previous consumption | ||||||||||||||||||
| 2 | Perception of problem by the consumer (problem poorly known or unknown, problem poorly controllable or uncontrollable, affects a sensitive public) | Not zoonotic or common | Null: clear perception by the consumer; problem well known, controllable, and no impact on the family; short-term effect; does not affect a sensitive public (children, pregnant women) | Low: clear perception by the consumer; problem well known, controllable, and no impact on the family; long-term effect; does not affect a sensitive public (children, pregnant women) | Moderate: clear perception by the consumer; problem poorly known, controllable, with an impact on the family; long-term effect; affects a sensitive public (children, pregnant women) | High: bad perception by the consumer; problem poorly known, difficult to control, with an impact on the family; long-term effect; affects a sensitive public (children, pregnant women) | |||||||||||||||||
| 3 | Potential impact of media | Null: no impact of media on consuming habits | Low: short-term and minor impact on consuming habits | Moderate: long-term but minor impact on consuming habits | High: major and long-lasting impact on consuming habits (rejection of a particular by-product) | ||||||||||||||||||
| 4 | Impact on animal welfare and biodiversity | Null: no impact on animal welfare and biodiversity: no slaughtering, no specific control measures applied to wildlife, no quarantine or containment of animals | Low: no slaughtering but limited control measures and limited containment of species at risk (domestic and wild animals) | Moderate: selective slaughtering of animals showing clinical signs in outbreaks, control and containment of species at risk (domestic and wild animals) | High: systematic slaughtering of domestic and wild animals (outbreaks and surveillance zones), mandatory quarantine, containment of domestic animals at risk | ||||||||||||||||||
*EU, European Union; YOPI, young, old, pregnant, immunosuppressed. †Common, pathogen able to cause a clinical disease in humans and animals but without a zoonotic characteristic (common source of contamination).
Characteristics of 40 experts who analyzed diseases of food-producing animals and zoonoses, Europe*
| Expert | Location | Sex | Background | Country | Field of expertise | Keywords | Categories of criteria |
|---|---|---|---|---|---|---|---|
| H. Amory | Univ | F | DVM, PhD, University Professor (Faculty of Veterinary Medicine) | Belgium | Equine internal medicine | Internal medicine, cardiology, echocardiography, infectious diseases | EP |
| J.-M. Bouquiau | Min | M | Agronomy Engineer, University Professor (Faculty of Agronomy) | Belgium | Agriculture economy | Agricultural economist, evaluation of losses, farmer, industry, prevision of indigenous brut production | EC |
| S. Brunet | Univ | M | Lic Political Science and Public Administration, PhD, Instructor in Political Science | Belgium | Sociology | Risk sociology, participative methods, interactions science/society | SO |
| Y. Coppieters | Univ | M | MD, PhD, University Professor (School of Public Health) | Belgium | Public health | Epidemiology, health promotion, adult formations, cardiovascular diseases | PH |
| G. Czaplicki | Lab | M | DVM, Head of a veterinary diagnostic Laboratory | Belgium | Laboratory diagnosis | Animal serology, bovine pathology, swine pathology, epidemiology, animal infectiology | EP |
| X. Demarche | EuroC | M | DVM, Administrator European Institution | International† | Agriculture economy | Agriculture, animal health, food hygiene, community expenditures, international trade | EC |
| M. Dominguez | FAO | F | DVM, FAO Global Early Warning System, Associate Professional Officer | Italy | Animal epidemiology | Epidemiology, veterinary public health, surveillance, arboviruses, international health | EP, EC, PC, PH, SO |
| P.-V. Drion | Univ | M | DVM, PhD, University Professor (Experimental methods of laboratory animals and ethics in animal experiments, University of Liege) | Belgium | Animal welfare | Animal ethics, laboratory animals, animal experimentation | SO |
| B. Duquesne | Univ | F | Lic Agronomy, PhD, University Professor (Faculty of Agronomy) | Belgium | Agriculture economy | Veterinarian, consumption, food safety, economy, agroalimentary industry | EC |
| F. Fecher | Univ | F | Lic Economics, PhD, University Professor (Faculty of Economics) | Belgium | Economy | Health economy, social economy, health systems, hospital financing | EC |
| S. Geerts | Univ | M | DVM, PhD, Dipl, EVPC, University Professor (Institute of Tropical Medicine, Animal Health Department, head of the Unit of Veterinary Protozoology) | Belgium | Parasitology | Tropics, parasitology, zoonosis, trypanosomiasis, cysticercosis | EP, EC, PC, PH, SO |
| J. Godfroid | Univ | M | DVM, PhD, University Professor (Professor at the Norwegian School of Veterinary Science, Section of Arctic Veterinary Medicine; Extraordinary Professor at the University of Pretoria, Faculty of Veterinary Science, Department of Veterinary Tropical Diseases) | Norway, South Africa | Bacteriology | Brucellosis, tuberculosis, cattle, diagnosis | EP, EC, PC, PH, SO |
| C. Gosset | Univ | F | MD, PhD, University Professor (School of Public Health, Faculty of Medicine) | Belgium | Public health | Public health, epidemiology, health observatory, health care, economics of health | EP, PC, EC, PH |
| L. Hallet | CVO | M | DVM, former Chief Veterinary Officer | Belgium | Control | Reportable diseases, veterinarian, rabies vaccination | EP |
| A. Huberty | CVO | M | DVM, Chief Veterinary Officer | Luxemburg | Control | Biosecurity, epidemiologic, surveillance, vigilance, risk assessment, identification | EP, EC, PC, PH, SO |
| N. Kirschvink | Univ | F | DVM, PhD, University Professor (Department of Veterinary Medicine; Unit of Integrated Research in Veterinary Medicine, Namur Research Institute for Life Sciences) | Belgium | Small ruminants | Animal production, sheep reproduction, ovine medicine, pathophysiology, respiratory diseases | EP |
| A. Leblond | Univ | F | DVM, PhD, Dipl European College Equine Internal Medicine, University Professor (Department of Horse Internal Medicine); RESPE scientific committee; ANSES | France | Equine internal medicine | Internal medicine, equids, epidemiology, infectious diseases, neurology | EP, PC |
| M. Lefèvre | Univ | F | Lic Economics, PhD (Department of Economics) | Belgium | Agriculture economy | Development economy, microeconomy, agricultural economy, dairy cattle,western Africa | EC |
| L. Lengelé | CVO | M | DVM, former Chief Veterinary Officer and head of veterinary Services; Delegated with OIE | International | Animal epidemiology | Veterinary public health, welfare of production animals, prevention and control of diseases, epidemiology | EP, EC, PC, PH, SO |
| P. Léonard | Univ | M | MD, Master in Acute Medicine, Master in Internal medicine, Master in tropical medicine, University Professor (Department of Infectious Diseases and Tropical Diseases, Liege University Hospital) | Belgium | Internal tropical medicine | Infectious diseases, immunodeficiency, tropical diseases, emerging diseases, internal medicine | PH |
| A. Linden | Univ | F | DVM, PhD, University Professor (Department of Infectious and Parasitic Diseases, Unit of Wildlife Health and Pathologies); Walloon Wildlife Health Monitoring Surveillance Network | Belgium | Wildlife | Wildlife, mycobacteria, bluetongue, bacteriology, pathology | EP |
| M. Lomba | ARSIA | M | DVM, Veterinary Diagnostic Laboratory | Belgium | Animal epidemiology | Diagnosis, epidemiology, cattle, communication | EC, SO |
| B. Losson | Univ | M | DVM, PhD, University Professor (Department of Infectious and Parasitic Diseases, Unit of Parasitology and Parasitic Diseases) | Belgium | Parasitology | Parasitology, parasitic zoonoses, vectors, biologic control, ectoparasites | EP |
| J. Mainil | Univ | M | DVM, PhD, University Professor (Department of Infectious and Parasitic diseases, Unit Bacteriology and Bacteriologic Diseases) | Belgium | Bacteriology | Bacteriology, pathogeny, genetics (prokaryotes), molecular epidemiology, plasmidology | EP |
| D. Marlier | Univ | M | DVM, PhD, Dipl, ECZM (small mammals), University Professor (Clinical Department of Small Animals and Equids, Unit of Birds, Lagomorphs and Rodents); University Vet Clinics | Belgium | Avian and lagomorphs medicine | Aviculture, rabbit farming, birds, rabbits, rodents | EP |
| Y. Milleman | Univ | M | DVM, Lecturer (Head of Department of Animal Productions and Public Health, Unit of Cattle and Poultry Diseases); Unit of Food Microbiology - Safety and Quality | France | Pathology of ruminants | Cattle, | EP, PC, EC |
| B. Moinet | Wallonia | M | DVM, Cabinet of Ministry of Agriculture | Belgium | Agriculture economy | Agriculture politics, agriculture economy, ministry of agriculture | EC, SO |
| J.-L. Moyen | Dep, Lab | M | DVM, Head of Dordogne Departmental Laboratory | France | Laboratory diagnosis | Tuberculosis, interferon, immunoserology, ruminants, PCR | PC |
| P. Mullier | CVO | M | DVM, Belgian Federal Agency for the Safety of the Food Chain, Director or French-speaking and German-speaking communities | Belgium | Control | Veterinarian, public function, sanitary policy, epidemiologic surveillance, epidemiologic vigilance | PC |
| B. Nicks | Univ | M | DVM, PhD, University Professor (Department of Animal Productions, Unit of Veterinary Ecology and Ethology) | Belgium | Animal welfare and ethics | Animal husbandry, environment, animal welfare, animal health | SO |
| L. Plee | FAO | M | DVM, Epidemiologist, Animal Health Service (AGAH) and ECTAD Technical Staff, situation officer at the CMC-AH, FAO | International | Animal epidemiology | Epidemiology, zoonoses, risk assessment, veterinary legislation, subacute encephalopathies | PC, SO |
| A. Raskin | CVO | M | DVM, Belgian Federal Agency for the Safety of the Food Chain | Belgium | Control | Classical swine fever, stamping out diseases, identification, brucellosis, database | PC |
| J.-M. Robijns | CVO | M | DVM, Belgian Federal Agency for the Safety of the Food Chain | Belgium | Control | Database management, animal identification and recording, animal products and by-products traceability, control of animal diseases, support programs | PC |
| B. Soumaré | Univ | M | DVM, MSc, PhD; Regional Influenza Advisor, USAID West Africa Office | Belgium | Animal epidemiology | Zoonoses, pandemic threats, epidemiology, risk analysis, socioeconomic analysis | PC |
| J. Tafforeau | ISP | M | MD, Scientific Institute of Public Health, Head of Unit Public Health and Surveillance | Belgium | Human epidemiology | Epidemiology, chronic diseases, health determinants, investigations, health priorities | PH |
| E. Thiry | Univ | M | DVM, PhD, University Professor (Department of Infectious and Parasitic Diseases, Unit of Virology and Viral Diseases) | Belgium | Virology | Virus, animal, emerging diseases, genetics | EP |
| M. Vandenheede | Univ | M | DVM, PhD, Lecturer (Department of Animal Productions, Unit of Veterinary Ecology and Ethology) | Belgium | Ethology and animal welfare | Domestic animals, behavior, welfare, ethology | SO |
| L. Vanholme | CVO | M | DVM, Belgian Federal Agency for the Safety of the Food Chain | Belgium | Control | Zoonoses, reporting, animal health monitoring, animal health eradication, emerging disease | PC |
| P. Vannier | ANSES | M | DVM, ANSES, Head of Animal Health and Welfare | France | Animal epidemiology | Animal health, virology, epidemiology, risk analysis, vaccinology | EP, EC, PC, PH, SO |
| S. Zientara | INRA | M | DVM, Master in Molecular Virology, Master in Epidemiology, PhD, Central Laboratory of Veterinary Research, Maisons-Alfort Topic (Equine Viral Diseases); Head of Virology and of the National Reference Laboratory for Foot-and Mouth Disease, Bluetongue, West Nile and African Horse Sickness | France | Virology | Foot-and-mouth disease, bluetongue, West Nile fever, equine viral diseases | EP |
*ID, identification; univ, University; DVM, Doctor of Veterinary Medicine; PhD, Doctor of Philosophy; EP, epidemiology; min, Ministry; EC, economy/trade; lic, license; SO, society; MD, Medical Doctor; PH, public health; Lab, Laboratory; EuroC, European Commission; FAO, Food and Agriculture Organization; PC, prevention/control; Dipl, diplomate; EVPC, European Parasitology Veterinary College; CVO, chief veterinary officer; RESPE, Réeseau d’Epidemio-Surveillance en Pathologie Equine; ANSES, French Agency for Food, Environmental and Occupational Health and Safety; OIE, World Organization for Animal Health; ARSIA, Regional Association of Animal Health and Identification; ECZM, European College of Zoological Medicine; Dep, Department; AGAH, Animal Production and Health Division of FAO; ECTAD, European Centre for Transboundary Animal Diseases; CMC-AH, Crisis Management Centre for Animal Health of FAO; USAID, United States Agency for International Development; ISP, Institute of Public Health; INRA, Institut National de la Recherche Agronomique. †International organizations.
Figure 1Weighting (mean no. points) of criteria for diseases of food-producing animals and zoonoses for 5 aspects of a pathogen proposed by experts, Europe. A) Epidemiology by 18 experts. A, illness rate; B, case-fatality rate; C, specificity of agents; D, mode of transmission; E, incubation period; F, clinical course; G, environmental persistence; H, epizootic potential; I, evolutive potential; J, cattle; K, small ruminants; L, swine; M, equines; N, poultry; O, lagomorphs; P, wildlife; Q, vector(s) or reservoir(s) in the European Union. B) Prevention/control by 16 experts. A, control of reservoir(s)/vector(s); B, vaccination; C, treatment; D, availability/quality of diagnostic tools; E, knowledge of pathogen; F, effectiveness of control; G, effectiveness of prevention; H, surveillance of pathogen. C) Economy/trade by 14 experts. A, loss of productivity; B, costs of mandatory slaughtering; C, costs of treatment and disinfection; D, costs of vaccination; E, limitation of importation-exportation; F, disturbance of supply/demand; G, impact on related sectors; H, impact on cattle industry; I, impact on small ruminants industry; J, impact on swine industry; K, impact on equine industry; L, impact on poultry industry; M, impact on rabbit industry; N, impact on wildlife industry; O, zoonotic impact (cost of illness); P, zoonotic impact (cost of prevention). D) Public health by 10 experts. A, zoonotic/common agent; B, classification of zoonoses; C, disease knowledge in humans; D, illness rate; E, case-fatality rate; F, contamination route; G, after effects; H, existing control plan; I, epidemic potential; J, vaccination; K, treatment; L, availability and quality of diagnostic tools. E) Society by 13 experts. Error bars indicate ± SD.
Figure 2Classification and regression tree analysis showing grouping of diseases of food-producing animals and zoonoses into 4 subgroups by using overall weighted scores per disease as input, Europe. A) High importance and significant importance. B) Moderate importance and relatively low importance. Numbers at the top indicate overall weighting scores of pathogens. Squares indicate means, and error bars indicate 95% CIs. Causative agents are shown in parentheses on the left. Values on the left in brackets are zoonotic aspects codes: 2, rare; 1, accidental; 3, frequent; 0, nonzoonotic/common. Values on the right are mean ± SD weighting scores. *Foot-and-mouth disease and Newcastle disease were considered zoonotic in this study.